J.Safra Asset Management Corp Buys Shares of 3,122 Alnylam Pharmaceuticals, Inc. $ALNY

J.Safra Asset Management Corp acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 3,122 shares of the biopharmaceutical company’s stock, valued at approximately $940,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ALNY. iA Global Asset Management Inc. raised its holdings in Alnylam Pharmaceuticals by 979.5% in the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after acquiring an additional 16,133 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $2,505,000. Hsbc Holdings PLC grew its position in shares of Alnylam Pharmaceuticals by 22.6% in the fourth quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock valued at $35,675,000 after purchasing an additional 16,503 shares during the period. Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $243,000. Finally, Keystone Investors PTE Ltd. purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $3,531,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This represents a 70.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on ALNY. Chardan Capital reiterated a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Citigroup dropped their price target on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a research report on Monday, August 3rd. Barclays cut their price target on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a research note on Monday, August 3rd. Truist Financial decreased their price target on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Finally, Needham & Company LLC lowered their price objective on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $393.86.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $228.65 on Monday. The business’s 50-day simple moving average is $272.86 and its 200 day simple moving average is $301.02. The company has a market cap of $30.60 billion, a P/E ratio of 42.50 and a beta of 0.30. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. Alnylam Pharmaceuticals, Inc. has a one year low of $197.81 and a one year high of $495.55.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.